First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Cervical cancer is the second-most common cancer in the world and is a leading cause of
cancer death among women in developing countries. Cisplatin-based chemotherapy +/-
bevacizumab have been recommended as the first-line treatment for patients who present with
metastatic (e.g. stage IVB), persistent, or recurrent cervical cancer. However, patients in
this setting are rarely curable. The immune checkpoint inhibitor (ICI) therapy, including
cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death-1 (PD-1), and programmed
death-ligand 1 (PD-L1) inhibitors, has revolutionized the treatment of several cancers. The
investigator previously reported the promising antitumor efficacy of camrelizumab (PD-1
inhibitor) combined with apatinib (VEGFR2 inhibitor) as second-line, or later, therapy in
patients with advanced cervical cancer. This randomized study is to assess the efficacy and
safety of first-line treatment with camrelizumab plus apatinib compared to the efficacy and
safety of paclitaxel and cisplatin/carboplatin plus bevacizumab in patients with stage IVB,
recurrent, or persistent cervical cancer.